The kinase inhibitor was approved for patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Chris Ryan
Advertisement
Managing Editor, OncLive
Articles by Chris Ryan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Contextualizing Lecanemab’s New Subcutaneous Weekly Starting Dose
5